Reports indicate that biopharma companies are using return-to-office requirements and hybrid work mandates to reshape R&D capacity, with employees in some locations facing role exits or relocation pressure. At EMD Serono, a WARN notice required R&D staff reporting to the Billerica institute to work onsite at least three days per week starting in early September, affecting remote employees living beyond the commute radius. Separately, Exelixis layoffs included remote staff in a broader workforce reduction tied to facility closure and planned reopening with more on-site roles. The combined updates point to how operating model decisions can translate into labor churn in research functions, not just corporate back-office roles. For the sector, the developments matter for talent retention and trial execution continuity, especially where R&D staff are concentrated in specific hubs and integration timelines are sensitive.